Azithromycin in the Treatment of M. Avium Complex Lung Disease

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators:	The University of Texas Health Science Center at Tyler Pfizer
Information provided by:	The University of Texas Health Science Center at Tyler
ClinicalTrials.gov Identifier:	NCT00599079

Purpose

To determine the safety and efficacy of azithromycin in the treatment of lung infection with M.avium complex and M. abscessus lung disease.

Condition	Intervention	Phase
Mycobacterium Avium Complex M. Abscessus	Drug: Azithromycin	Phase IV

Drug Information available for: Azithromycin

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Open, Noncomparative Trial of Azithromycin in the Treatment of M.Avium Complex (MAC) Lung Disease

Further study details as provided by The University of Texas Health Science Center at Tyler:

Primary Outcome Measures:

Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be at one month, then at three months, then at six months, then annually and prn for life ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Microbiological cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be at one month, then at three months, then at six months, then annually and prn for life ] [ Designated as safety issue: Yes ]

Enrollment:	66
Study Start Date:	February 1993
Estimated Primary Completion Date:	August 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1	Drug: Azithromycin Dosage dependent on clinical factors such as age, weight and patient-specific health status

Eligibility

Criteria

Inclusion Criteria:

Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; abnormal CXR consistent with M. avium lung disease; absence of other lung pathogens (except for the coexistence of M. abscessus).
Age 18 and older
Pretreatment isolate of M. avium complex available for MIC determination

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00599079

Locations

United States, Texas
The University of Texas Health Science Center at Tyler
Tyler, Texas, United States, 75708

Sponsors and Collaborators

The University of Texas Health Science Center at Tyler

Pfizer

Investigators

Principal Investigator:

Richard J Wallace Jr., M.D.

The University of Texas Health Science Center at Tyler

More Information

Responsible Party:	The University of Texas Health Science Center at Tyler ( Richard J. Wallace Jr., M.D. )
Study ID Numbers:	340
Study First Received:	January 11, 2008
Last Updated:	January 11, 2008
ClinicalTrials.gov Identifier:	NCT00599079
Health Authority:	United States: Food and Drug Administration

Keywords provided by The University of Texas Health Science Center at Tyler:

MAC

Study placed in the following topic categories:

Bacterial Infections
Gram-Positive Bacterial Infections
Respiratory Tract Diseases
Azithromycin
Lung Diseases

Mycobacterium Infections
Mycobacterium avium complex infection
Mycobacterium Infections, Atypical
Mycobacterium avium-intracellulare Infection

Additional relevant MeSH terms:

Anti-Infective Agents
Anti-Bacterial Agents
Therapeutic Uses
Pharmacologic Actions
Actinomycetales Infections

ClinicalTrials.gov processed this record on January 14, 2009